Bumetanide Inj Rx
Generic Name and Formulations:
Bumetanide 0.25mg/mL; contains benzyl alcohol.
Various generic manufacturers
Indications for Bumetanide Inj:
Initially 0.5–1mg IM or IV. May give 1–2 more doses at 2–3 hour intervals; max 10mg/day.
<18yrs: not recommended.
Anuria. Infants. Hepatic coma. Severe electrolyte depletion.
Hepatic cirrhosis. Ascites. Progressive renal disease. Gout. Diabetes. Postsympathectomy. Monitor electrolytes, blood, liver function. May need K+ supplementation. K+ losing nephropathy. Discontinue if renal dysfunction progresses. Aldosterone excess. Ventricular arrhythmias. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
May increase digitalis, lithium toxicity. Hypokalemia with digitalis, diuretics in CHF. Alcohol, CNS depressants increase orthostatic hypotension. Avoid probenecid, indomethacin. Ototoxicity may be potentiated with aminoglycosides.
Muscle cramps, dizziness, hypotension, headache, nausea, encephalopathy, ototoxicity, rash, fluid or electrolyte imbalance, hyperglycemia, hyperuricemia, blood dyscrasias.
Formerly known under the brand name Bumex.
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D